Multiple Dose, Steady State-Partial reference replicate [Design Issues]

posted by jag009  – NJ, 2018-07-17 08:34 (2473 d 10:25 ago) – Posting: # 19074
Views: 4,686

❝ Please help in understanding whether it is possible to conduct “An open-label, randomized, Multiple Dose, Steady State, two treatments, three periods, three sequence, three way, Reference Replicated crossover bioequivalence study” for USFDA Submission?


Why you are doing multiple dose? FDA does not like multiple dose (unless you are doing b2).

J

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
18 visitors (0 registered, 18 guests [including 4 identified bots]).
Forum time: 18:59 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5